Understanding Oral Lichen Planus

Oral lichen planus (OLP) is a chronic, T-cell mediated autoimmune inflammatory condition affecting the stratified squamous epithelium of the oral mucosa. With an estimated prevalence of 1.0–2.0% in the general population, it primarily affects middle-aged adults (mean age of onset: 50–60 years) and exhibits a female predominance of approximately 1.4:1 to 2:1.

OLP is now understood as a cell-mediated autoimmune process in which CD8⁺ cytotoxic T lymphocytes are activated against basal keratinocytes. The initiating event remains unknown, but prevailing models involve an exogenous or endogenous trigger (such as a viral infection or contact allergen) that alters basal keratinocyte surface antigens, leading to T-cell activation via upregulated MHC Class I molecules. This triggers a cascade of apoptosis mediated by the Fas-FasL pathway and the release of granzyme B and perforin from activated CD8⁺ cells, progressively destroying the basal cell layer.

This pathogenesis explains the histopathological hallmarks visible on biopsy: a dense, band-like lymphocytic infiltrate immediately subjacent to the epithelium (lichenoid infiltrate), liquefactive degeneration of the basal cell layer, and "saw-tooth" rete ridges. Direct immunofluorescence often reveals fibrinogen deposition at the basement membrane zone and IgM-staining cytoid bodies representing apoptotic keratinocytes.

Clinical Subtypes and Diagnosis

OLP presents in several distinct clinical forms, and patients frequently exhibit more than one subtype simultaneously:

Reticular OLP is the most common form (50–65% of cases), characterized by fine, interlacing white lines (Wickham striae) most commonly on the buccal mucosa bilaterally. These striae represent areas of hyperkeratosis and are often asymptomatic, discovered incidentally during routine dental examination. Their bilateral, symmetrical distribution is pathognomonic and helps distinguish OLP from contact lichenoid reactions, which are typically unilateral.

Erosive (erythematous) OLP accounts for 20–35% of cases and represents the most symptomatic subtype. Patients present with atrophic, erythematous areas with superficial ulcerations covered by a fibrinous pseudomembrane. The pain can be severe, exacerbated by spicy, acidic, or hot foods, and significantly impairs quality of life. The attached gingiva and buccal mucosa are the most commonly affected sites.

Additional subtypes include plaque-type OLP (resembling leukoplakia, with homogenous white plaques typically on the dorsum of the tongue), papular OLP (small, discrete white papules, often coalescing), atrophic OLP (thinned, red mucosa with minimal striae), and bullous OLP (rare, characterized by fluid-filled bullae that rapidly rupture into erosions).

Diagnosis requires clinical examination and histopathological confirmation through incisional biopsy. A 2016 position paper by the American Academy of Oral and Maxillofacial Pathology recommends biopsy of all suspected OLP lesions to confirm the diagnosis and, critically, to rule out epithelial dysplasia or squamous cell carcinoma.

Malignant Transformation Risk

The most controversial and clinically significant aspect of OLP management is its malignant potential. The World Health Organization (WHO) classifies OLP as an oral potentially malignant disorder (OPMD), but the magnitude of this risk has been debated for decades.

A 2016 systematic review and meta-analysis published in Oral Diseases included 20 studies with 7,816 patients and reported a pooled malignant transformation rate of 1.09% (95% CI: 0.69–1.64%). More recent data from a large Swedish cohort study (2021, n = 7,735) found a standardized incidence ratio of 6.28 (95% CI: 5.60–7.01), indicating a sixfold increased risk compared to the general population.

The erosive/atrophic subtype carries the highest risk, as the chronic epithelial damage and regenerative proliferation in these lesions may increase the probability of malignant mutations. Clinically, suspicious signs include induration, fixation to underlying tissues, non-healing ulceration for more than 2–3 weeks, and rapid increase in lesion size.

Current consensus guidelines recommend regular follow-up every 3–6 months for erosive OLP, and every 6–12 months for asymptomatic reticular OLP, with a low threshold for repeat biopsy of any clinically suspicious area.

Management Hierarchy

Management of OLP is directed at symptom control, as no cure currently exists. The therapeutic ladder proceeds from local to systemic interventions:

First-line: Topical corticosteroids remain the cornerstone of treatment. Medium-to-high potency agents (fluocinonide 0.05% gel, clobetasol propionate 0.05% ointment, betamethasone 0.05%) are applied directly to affected mucosa 2–4 times daily. The vehicle matters: gels and ointments adhere better to moist mucosa than creams. A 2014 Cochrane review concluded that topical corticosteroids produce clinically significant pain reduction in OLP, though the evidence quality was rated as low to moderate due to heterogeneous outcome measures across trials.

Second-line: Topical calcineurin inhibitors—tacrolimus 0.1% ointment and pimecrolimus 1% cream—offer an alternative for steroid-resistant cases. A 2020 RCT by Vohra et al. compared tacrolimus 0.1% with clobetasol 0.05% in 60 patients and found comparable efficacy at 12 weeks, with tacrolimus showing a slight advantage for erosive lesions. However, the FDA's black box warning regarding a potential (though unproven) malignancy risk with long-term calcineurin inhibitor use warrants caution.

Third-line: Systemic therapies including oral prednisolone (for acute severe exacerbations), hydroxychloroquine (an immunomodulator with a favorable safety profile), methotrexate, mycophenolate mofetil, and biologics (rituximab, ustekinumab) are reserved for severe, recalcitrant, and widespread disease. These require specialist supervision and regular monitoring for adverse effects including hepatotoxicity, nephrotoxicity, and myelosuppression.

Adjunctive measures—avoiding spicy foods, acidic beverages, alcohol-based mouthwashes, and maintaining excellent oral hygiene—can significantly reduce symptom burden. The chronic nature of OLP means that the therapeutic relationship between patient and clinician, built on realistic expectations and regular follow-up, is essential for long-term management success.